LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Inicio・Lista de Acciones・Krystal Biotech Inc

Krystal Biotech Inc

Cerrado

SectorSanidad

204.81 1.81

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

196.37

Máximo

207.85

Métricas clave
By Trading Economics
Ingresos	41M 79M
Ventas	1.8M 98M
P/B Media del Sector	29.96 105.69
Margen de beneficios	81.15
Empleados	275
EBITDA	10M 50M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+8.85% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	278M 5.8B
Apertura anterior	203
Cierre anterior	204.81

Noticias sobre sentimiento de mercado

By Acuity

50%

185 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

133.221 / 169.73 Soporte y Resistencia

Krystal Biotech Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 nov 2025, 17:45 UTC

Ganancias

Principales Movimientos del Mercado

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Ganancias

Principales Movimientos del Mercado

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14 nov 2025, 16:15 UTC

Principales Movimientos del Mercado

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14 nov 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Charlas de Mercado

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Ganancias

Adquisiciones, fusiones, absorciones

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Ganancias

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Charlas de Mercado

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Adquisiciones, fusiones, absorciones

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Charlas de Mercado

Ganancias

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Charlas de Mercado

Ganancias

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Charlas de Mercado

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Charlas de Mercado

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Charlas de Mercado

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov 2025, 16:38 UTC

Charlas de Mercado

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14 nov 2025, 16:30 UTC

Adquisiciones, fusiones, absorciones

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 nov 2025, 16:28 UTC

Charlas de Mercado

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14 nov 2025, 15:59 UTC

Charlas de Mercado

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14 nov 2025, 15:06 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 nov 2025, 15:06 UTC

Charlas de Mercado

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Comparación entre iguales

Cambio de precio

Krystal Biotech Inc previsión

Precio Objetivo

By TipRanks

8.85% repunte

Estimación a 12 Meses

Media 221 USD 8.85%

Máximo 255 USD

Mínimo 198 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Krystal Biotech Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Krystal Biotech Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

133.221 / 169.73Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentimiento

By Acuity

185 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.